Anondita Medicare Q4 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹1,794 Cr
- P/E
- 53.64
- ROE
- 40.22%
- Price to sales
- 13.06
- Debt to equity
- 0.26
- 52W high / low
- ₹1,233 / ₹600
- EBITDA margin
- 36.89%
- Net profit margin
- 24.96%
- Promoter holding
- 59.26%
- Sales (last year)
- ₹137 Cr
Founded in March 2024, Anondita Medicare Limited manufactures flavored male condoms, with its flagship product branded as “COBRA.”[1]
Guidance scorecard · Q4 FY26 call
What Anondita Medicare's management guided
and where it ranks in Personal Products
Personal Products
RevenueQ4 FY26 call
40%+- Company expects major revenue growth driven by increased capacities and international market expansion.
- Total manufacturing capacity increased from 562 million to 806 million condoms annually, with initial utilization expected around 75%.
- Anticipates doubling revenue to INR 1,000 crores within the next 2 years.
- Expects 25% capacity addition to contribute INR 325 crores turnover in the coming year.
- Focus on export markets including South Africa (1 billion pieces tender over 5 years), Brazil, and others, to drive volume growth.
- Plans to launch innovative products (spiral condoms, non-latex male condoms, female condoms) to capture market share.
- Government business expected to grow moderately (~5-10%), but primary focus on own brand "Cobra" and exports with higher margins.
2 more points from Anondita Medicare's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
Up 2%+See what Anondita Medicare said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- The company undertook significant capex in FY 2026, adding to property, plant, and equipment, with CWIP also increased.
- Total capex done last year was approximately INR 62 crores; out of that, INR 24 crores was already spent, expanding capacity to 307 million units.
- Additional capacity under WIP is expected to increase capacity by 250 million units, aiming for a turnover of around INR 325 crores from this expansion.
- The capex was completed by end of December, so depreciation expense impact in FY 2026 was limited to one quarter.
- The company has patented in-house manufacturing machines, which facilitate faster and lower-cost capacity expansion compared to competitors.
2 more points from Anondita Medicare's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what Anondita Medicare said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Rising- Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year.
- The company has secured a single rate contract as the sole L1 supplier to the Government of India National AIDS Control Society, ensuring continuous government orders.
- Registered in South Africa for the next five years with a requirement of 1 billion pieces annually; expects to execute about 25% of that order this year, leading to significant revenue jump.
- Order pipeline includes international orders from countries like Kenya, Uzbekistan, Brazil, and South Africa under their own brand "Cobra."
2 more points from Anondita Medicare's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- 1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Personal Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | Anondita Medi.This stock | 40%+ | Up 2%+ | ₹1,858 Cr | 55.5 |
| 2 | 40%+ | Flat | ₹408 Cr | 36.4 | |
| 3 | Honasa Consumer Ltd | 20–40% | Up 0–2% | ₹14,422 Cr | 57.1 |
| 4 | 10–20% | Flat | ₹83,720 Cr | 39.4 | |
| 5 | 10–20% | Flat | ₹64,856 Cr | 32.7 | |
| 6 | 10–20% | Flat | ₹15,704 Cr | 20.7 |
Sign up free to see every company in the sector ranking and track Anondita Medicare.
Pro shows every company guiding 40%+ revenue growth →Full Personal Products rankingFinancials of Anondita Medicare
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Anondita Medicare
Quarterly Results
Quarter-by-quarter operating performance
Financials of Anondita Medicare
Profit & Loss
Annual income statement trend
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales + | 77 | 137 |
| Expenses + | 51 | 87 |
| Operating Profit | 26 | 51 |
| OPM % | 33% | 37% |
| Other Income + | 0 | 1 |
| Interest | 3 | 4 |
| Depreciation | 1 | 1 |
| Profit before tax | 22 | 47 |
| Tax % | 25% | 27% |
| Net Profit + | 16 | 34 |
| EPS in Rs | 11.88 | 18.49 |
| Dividend Payout % | 0% | 0% |
Financials of Anondita Medicare
Balance Sheet
Capital structure and asset base
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 13 | 18 |
| Reserves | 25 | 111 |
| Borrowings + | 27 | 34 |
| Other Liabilities + | 13 | 22 |
| Total Liabilities | 78 | 185 |
| Fixed Assets + | 14 | 84 |
| CWIP | 6 | 0 |
| Investments | 3 | 0 |
| Other Assets + | 55 | 101 |
| Total Assets | 78 | 185 |
Financials of Anondita Medicare
Cash Flows
Operating, investing and financing cash movement
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity + | -10 | 11 |
| Cash from Investing Activity + | -23 | -63 |
| Cash from Financing Activity + | 33 | 61 |
| Net Cash Flow | -0 | 9 |
| Free Cash Flow | -30 | -52 |
| CFO/OP | -38% | 28% |
Financials of Anondita Medicare
Ratios
Working capital efficiency and return ratios
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 127 | 138 |
| Inventory Days | 141 | 126 |
| Days Payable | 40 | 49 |
| Cash Conversion Cycle | 228 | 215 |
| Working Capital Days | 129 | 163 |
| ROCE % | 44% |
Momentum score · price trend
31 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +57.8% | 88% |
| Last 6 months | −6.0% | 44% |
| Last 3 months | −10.5% | 43% |
The price is 23.8% below its all-time high of ₹1,233.15 (24 Jun 2026). Stocks more than 20% below their peak have their score halved, so 61 became 31.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Anondita Medicare: 0.4 × 88 + 0.4 × 44 + 0.2 × 43 = 61, halved to 31 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Anondita Medicare's management said in earlier quarters
Others in Personal Products this season
- JHS Svendgaard Laboratories (Q2 FY27)
2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%. Key results statement takeaways from JHS Svendgaard Labor
- Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
- Recode Studios (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
- Godrej Consumer (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej